AIMS The onset of the COVID-19 pandemic saw the suspension of centre-based cardiac rehabilitation (CBCR) and has underscored the need for home-based cardiac telerehabilitation (HBCTR) as a feasible alternative rehabilitation delivery model. Yet, the effectiveness of HBCTR as an alternative to Phase 2 CBCR is unknown. We aimed to conduct a meta-analysis to quantitatively appraise the effectiveness of HBCTR. METHODS AND RESULTS PubMed, EMBASE, CENTRAL, CINAHL, Scopus, and PsycINFO were searched from inception to January 2021. We included randomized controlled trials (RCTs) comparing HBCTR to Phase 2 CBCR or usual care in patients with coronary heart disease (CHD). Out of 1588 studies, 14 RCTs involving 2869 CHD patients were included in this review. When compared with usual care, participation in HBCTR showed significant improvement in functional capacity {6-min walking test distance [mean difference (MD) 25.58 m, 95% confidence interval (CI) 14.74-36.42]}; daily step count (MD 1.05 K, 95% CI 0.36-1.75) and exercise habits [odds ratio (OR) 2.28, 95% CI 1.30-4.00)]; depression scores (standardized MD -0.16, 95% CI -0.32 to 0.01) and quality of life [Short-Form mental component summary (MD 2.63, 95% CI 0.06-5.20) and physical component summary (MD 1.99, 95% CI 0.83-3.16)]. Effects on medication adherence were synthesized narratively. HBCTR and CBCR were comparably effective. CONCLUSION In patients with CHD, HBCTR was associated with an increase in functional capacity, physical activity (PA) behaviour, and depression when compared with UC. When HBCTR was compared to CBCR, an equivalent effect on functional capacity, PA behaviour, QoL, medication adherence, smoking behaviour, physiological risk factors, depression, and cardiac-related hospitalization was observed.

中文翻译：

---

以家庭为基础的心脏远程康复作为冠心病第二阶段心脏康复的替代方案的有效性：系统评价和荟萃分析。

目标 COVID-19 大流行的爆发导致中心心脏康复 (CBCR) 的暂停，并强调了将家庭心脏远程康复 (HBCTR) 作为可行的替代康复提供模式的必要性。然而，HBCTR 作为第 2 阶段 CBCR 的替代方案的有效性尚不清楚。我们旨在进行荟萃分析以定量评估 HBCTR 的有效性。方法和结果 检索了 PubMed、EMBASE、CENTRAL、CINAHL、Scopus 和 PsycINFO 从开始到 2021 年 1 月。我们纳入了比较 HBCTR 与 2 期 CBCR 或冠心病 (CHD) 患者常规护理的随机对照试验 (RCT)。在 1588 项研究中，14 项 RCT 涉及 2869 名 CHD 患者。与平时的护理相比，参与 HBCTR 显示功能能力显着改善 {6 分钟步行测试距离 [平均差 (MD) 25.58 m，95% 置信区间 (CI) 14.74-36.42]}；每日步数 (MD 1.05 K, 95% CI 0.36-1.75) 和运动习惯 [优势比 (OR) 2.28, 95% CI 1.30-4.00)]；抑郁评分（标准化 MD -0.16, 95% CI -0.32 至 0.01）和生活质量 [简短的心理成分总结（MD 2.63, 95% CI 0.06-5.20）和身体成分总结（MD 1.99, 95% CI 0.83） -3.16)]。叙述性地综合了对药物依从性的影响。HBCTR 和 CBCR 相当有效。结论 与 UC 相比，在 CHD 患者中，HBCTR 与功能能力、体力活动 (PA) 行为和抑郁症的增加有关。当 HBCTR 与 CBCR 进行比较时，对功能能力的等效影响，